

AD \_\_\_\_\_

Award Number: W81XWH-12-1-0340

TITLE: Targeting Prostate Cancer Cells by Combined Oxidative Stress Induction and Androgen Receptor Antagonism

PRINCIPAL INVESTIGATOR: Zhihui Qin

CONTRACTING ORGANIZATION: Wayne State University  
Detroit, MI 48201

REPORT DATE: August 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE August 2015		2. REPORT TYPE Annual		3. DATES COVERED 1 Aug 2014 - 21 Jul 2015	
4. TITLE AND SUBTITLE  Targeting Prostate Cancer Cells by Combined Oxidative Stress Induction and Androgen Receptor Antagonism				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0340	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)  Zhihui Qin  E-Mail: zqin@wayne.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Wayne State University (WSU), 259 Mack Ave, Detroit, MI, 48201;  University of Illinois at Chicago (UIC), 809 S. Marshfield Ave. Chicago, IL, 60612-4305				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Efficient synthetic routes were developed for the synthesis of Enzalutamide (Enz, MDV-3100) and EPI-001 derived hybrid drugs that target AR C-terminal ligand binding domain or N-terminal domain meanwhile inducing oxidative stress. Five classes of hybrid drugs have been designed and synthesized, i.e. Enz-PL (e.g. compd <b>28</b> ), Enz-catechol (e.g., compds <b>29, 30</b> ), Enz-HDACi (e.g., compds <b>24, 31, 33</b> ), chirally pure EPI scaffold carrying alternative electrophiles (i.e. compds <b>53, 55, 58</b> and <b>60</b> ). Biological assays, e.g., anti-proliferation assay, AR luciferase reporter assay and visualization of AR distribution in human prostate stromal cells were successfully established in collaborator's lab and will be used to study novel multifunctional hybrid drugs. Effects of Enz and piperlongumine (PL) on LAPC4 cell proliferation were also investigated, both compounds inhibited R1881-induced cell proliferation at 10 $\mu$ M but not at 1 $\mu$ M in single drug treatment. After 72h treatment, Enz (10 $\mu$ M) and PL (10 $\mu$ M) combination significantly inhibited LAPC4 cell growth compared to Enz treatment alone, the inhibitory effect was also stronger than PL single treatment, but was not statistically significant. Further experiments using combinations with different doses will be conducted. It would be straightforward to expand hybrid drug/drug combination libraries and to conduct structure-activity relationship studies based on current accomplishments.					
15. SUBJECT TERMS Key Words: oxidative stress, AR antagonist, anti-androgens, hybrid drug, drug combinations					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	3	19b. TELEPHONE NUMBER (include area code)

Grant had been temporally unavailable since PI left UIC on September 12, 2013 and joined Wayne State University as an Assistant Professor. The award was waiting for the pending transfer to be completed. No research had been performed during this period of time.

Grant transfer was completed on July 22, 2015. Research have been resumed and we are successfully making progress at this moment. New results will be reported next year (due on Aug 21, 2016). The support from DoD is highly appreciated!